Location History:
- Little Rock, AR (US) (2003 - 2012)
- New Haven, CT (US) (2016 - 2018)
- Orange, CT (US) (2013 - 2021)
Company Filing History:
13 out of 836 
6 out of 1,327 
2 out of 11 Years Active: 2003-2021
Title: Innovations in Cancer Treatment: The Patented Works of Alessandro D. Santin
Introduction: Alessandro D. Santin, located in Little Rock, Arkansas, is a distinguished innovator with a remarkable portfolio of 19 patents. His work primarily focuses on groundbreaking approaches to cancer treatment, particularly in the realm of immunotherapy and targeted drug conjugates.
Latest Patents: Santin's most recent innovations include two significant patents. The first patent details "Methods of identifying patients responsive to immunotherapeutic strategies." This invention provides a method for determining if a mammal's cancerous tumor, specifically one associated with a hypermutator phenotype for the DNA Polymerase epsilon (POLE) gene, is more mutated compared to normal cells. This assessment further facilitates the selection of patients with immunogenic tumors that may benefit from immunotherapy.
The second patent, "Duocarmycin ADCs for use in treatment of endometrial cancer," relates to antibody-drug conjugates containing duocarmycin that are designated for treating human solid tumors expressing HER2, notably endometrial cancer and uterine serous carcinoma. This innovative approach specifically targets tumors with a HER2 IHC status of 2- or 1+ and HER2 FISH negative tissue status.
Career Highlights: With a career that encompasses prestigious educational institutions, Santin has made significant contributions to cancer research. His tenure at the University of Arkansas and Yale University has shaped his expert understanding of oncology and innovative therapeutic strategies.
Collaborations: Throughout his career, Santin has worked alongside prominent researchers, including Timothy J. O'Brien and Martin J. Cannon. These collaborations have fostered a rich environment for innovation and have contributed to the significant advancements in cancer treatments.
Conclusion: Alessandro D. Santin exemplifies the spirit of innovation in the field of oncology. His 19 patents reflect his commitment to improving cancer treatment, particularly through personalized medicine and targeted therapies. As the landscape of cancer treatment continues to evolve, innovators like Santin are at the forefront, paving the way for more effective and tailored interventions.